Do ACE inhibitors/angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis

Drugs and Aging

Volumn 24, Issue 11, 2007, Pages 945-955

  Trewet, CoraLynn B ^a   Shireman, Theresa I ^b,c   Rigler, Sally K ^b,c   Howard, Patricia A ^d,e  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c Landon Center on Aging   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors, therapeutic use; Angiotensin II receptor antagonists, therapeutic use; Elderly; Heart failure, treatment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OMAPATRILAT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 36048935775     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724110-00006     Document Type: Article

References (42)

1. American Heart Association. Heart disease and stroke statistics: 2004 update. Dallas (TX): American Heart Association, 2003
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-13
3. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
4. Cohn JN, Archibald DG, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10
5. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
6. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35
7. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362 (9386): 777-81
8. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6
9. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693-704
10. Buch P, Soren R, Steen Z, et al. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 2005; 26: 145-52
11. Abarca J, Malone DC, Armstrong EP, et al. Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization. Pharmacotherapy 2004; 24 (3): 351-7
12. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104
13. Weintraub WS, Kawabata H, Tran M, et al. Cost of heart failure in patients receiving beta-blockers and angiotensin-converting enzyme inhibitors. Clin Drug Invest 2004; 24 (5): 255-65
14. Luthi J, Lund M, Sampietro-Colom L, et al. Readmissions and the quality of care in patients hospitalized with heart failure. Int J Qual Health Care 2003; 15 (5): 413-21
15. Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin- converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure: SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med 2000; 160 (1): 53-60
16. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy 1999; 19 (11): 1296-307
17. Antonelli Incalzi R, Pedone C, Pahor M, et al. Trends in prescribing ACE-inhibitors for congestive heart failure in elderly people. Aging Clin Exp Res 2002; 14 (6): 516-21
18. Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998; 158 (10): 1074-80
19. Bouvy ML, Heerdink ER, Leufkens HG, et al. Patterns of pharmacotherapy in patients hospitalized for congestive heart failure. Eur J Heart Fail 2003; 5 (2): 195-200
20. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990-2002. J Am Coll Cardiol 2003; 41 (1): 69-72
21. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 1998; 21 (2): 103-8
22. Hope CJ, Jingwei W, Wanzhu T, et al. Association of medication adherence, knowledge and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm 2004; 61: 2043-9
23. Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80: 437-41
24. Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004 Jun 2; 43 (11): 2036-43
25. Practice Management Information Corporation (PMIC). Classification of diseases, 9th revision: clinical modification. 6th edition. Los Angeles (CA): PMIC, 2002
26. Ahmed A, Allman RM, Delong JF, et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 2002; 95 (7): 703-10
27. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004; 27 (9): 2149-53
28. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37 (9): 846-57
29. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55 (8): 886-91
30. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366 (9502): 2005-11
31. Steiner JF, Fihn SD, Blair B, et al. Appropriate reductions in compliance among well-controlled hypertensive patients. J Clin Epidemiol 1991; 44 (12): 1361-71
32. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161 (4): 692-9
33. Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 1996; 86 (12): 1805-8
34. Howard PA, Shireman TI, Dhingra A, et al. ACE inhibitor patterns of use in elderly Medicaid patients with heart failure. Am J Geriatr Cardiol 2002; 11: 287-94
35. Rochon PA, Sykora K, Bronskill SE, et al. Use of angiotens-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community. J Gen Intern Med 2004; 19: 676-83
36. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2002; 362: 772-6
37. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996 Dec; 49 (12): 1373-9
38. Delahaye F, de Gevigney G. Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established? J Am Coll Cardiol 2000; 36: 2096-7
39. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health 1997; 87: 643-8
40. Croft JB, Giles WH, Roegner RH, et al. Pharmacologic management of heart failure among older adults by office-based physicians in the United States. J Fam Pract 1997; 44 (4): 382-90
41. Goff Jr DC, Pandey DK, Chan FA, et al. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi heart project. Arch Intern Med 2000; 160 (2): 197-202
42. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004; 43: 317-27